Oncomine NGS Assays for Clinical Oncology Research

The Oncomine Precision Assay on the Genexus System is a focused multigene panel that detects a broad range of genomic alterations across 50 genes from solid tumor and liquid biopsy samples.

Requiring only 20 minutes of hands-on time with two touchpoints, the highly automated system allows you to report NGS results as soon as the next day for integration with your immunohistochemistry results. In addition, a high success rate using only 10 ng of DNA/RNA means that more samples can be tested with results, even for small and challenging samples.

Advancements in precision medicine are driving the need for comprehensive genomic profiling (CGP) as oncology researchers continue to explore the utility of targeted therapies and immunotherapies. CGP facilitates simultaneous analysis of a broad range of biomarkers in one test to help maximize insights into the underlying oncogenic drivers in a timely manner.

Oncomine CGP assays include the Oncomine Comprehensive Assay v3 and the Oncomine Comprehensive Assay Plus. Both assays can be run on the Genexus System and Ion GeneStudio S5 system.

Leveraging proven Ion Torrent technology, these assays are complete, easy, fast, and robust solutions that can help you meet your laboratory research needs, even with varying levels of NGS expertise.

The Oncomine BRCA Assay is a highly automated BRCA sequencing solution that can be run on the Genexus System and Ion GeneStudio S5 system.

Laboratories can detect BRCA somatic and germline mutations, including large genomic rearrangement, without the need for multiple technologies in a specimen-to-report workflow that delivers results in as soon as the next day.

Whether you’re looking at multiple targets or just a few, our liquid biopsy NGS assays combine the power of Ion Torrent technology with cfDNA assays, advanced rare cell isolation, manual or automated cell-free DNA extraction, and digital PCR tools. Together, these solutions enable you to retrospectively assess cancer research samples throughout all stages.

With the Oncomine Myeloid Assay GX v2 on the Genexus System, you can get a comprehensive myeloid mutational profile from a single NGS run with next-day results. A highly integrated workflow lets you go from specimen to report with only 20 minutes of hands-on time and two user touch points. It’s never been easier to implement myeloid NGS testing in your lab.

The Ion Torrent Oncomine Myeloid MRD assays (RUO) on the Ion GeneStudio S5 System are a complete NGS testing solution for myeloid measurable residual disease (MRD) research.

Highly sensitive Ion AmpliSeq HD technology enables a limit of detection as low as 0.05% allele frequency.

Unlike traditional methods, NGS allows you to obtain informative data across a broad range of biomarkers simultaneously. A DNA and an RNA assay enable comprehensive assessment of genetic alterations, including SNVs, indels, and gene fusions.

Oncomine immune repertoire assays target B-cell and T-cell receptor chains with extremely high sensitivity and specificity for clonality assessment, rare clone detection, and somatic hypermutation analysis of lymphoid neoplasm samples.

Oncomine Tumor Mutation Load Assay

Tumor mutational burden (TMB) is an emerging biomarker that is rapidly gaining traction within the immuno-oncology research field. Recent studies have demonstrated that patients with higher TMB are more likely to respond to checkpoint inhibitor therapies.

The Oncomine Tumor Mutation Load Assay allows for simultaneous assessment of TMB and variant profiling in one run with low input requirements.